{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6a51087473fcc6a8a763d8cd?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial ","description":"<p>During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The discussion was chaired by Jacob Soumerai and featured Gilles Salles, Ulrich Jäger, Sonali Smith, Martin Dreyling, Astrid Pavlovsky, Michael Dickinson, and Jennifer Crombie. </p><p><br></p><p>Soumerai presented an overview of the SEQUOIA trial, efficacy and safety data, and key takeaways. </p><p><br></p><p>This educational resource is independently supported by BeOne Medicines. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p>","author_name":"Scientific Education Support"}